The Cornell Club of North East Ohio along with sponsors McGladrey and Jones Day are pleased to present a Healthcare investing session to cover investing ”from concept to venture” to “Private Equity and beyond” followed by a VIP Fundraising Event.
The Healthcare Investing Session will be held in the CCF Lerner Research Institute in the Genomics Building in Room NE1-205. Networking will be from 5:30 to 6:15 and the panel will run from 6:15 to 7:30 PM.
The panel will be moderated by Mark Brandt '86, and include Dr. Paul DiCorleto, Ph.D '78 Chair of the Cleveland Clinic Lerner Research Institute, and will include Joseph Ibrahim from the Riverside Company of Cleveland, Geoffrey B. Thrope Founder and CEO of NDI, and Dennis D. Stripe, President of OrthoHelix Surgical Designs.
There will be snacks and beverages at the Healthcare Investing Session which will also be free however you must sign up below as space is limited. Parking will be Valet, drive to the end of East 96th Street, South of Carnegie where valet parkers will be waiting.
Following the Healthcare Investing Session, a VIP Fundraising dinner with our panelist will be held at Table 45 at the Intercontinental Hotel across the street from the Lerner Research Institute from 7:45 to 9:45 – space is very limited for this and your entire donation of $150 per person will go to the Scholarship fund of the Cornell Club of NEO a 501c3.
Joseph Ibrahim is a Principal at The Riverside Company, a global private equity firm with $3.4 billion in assets under management. Mr. Ibrahim is responsible for evaluation of healthcare acquisitions in North America, Europe and the Asia-Pacific region. He also oversees Riverside’s healthcare specialization, and helps determine and maintain the firm’s healthcare investment strategy. Riverside is among the world’s most active generalist investors, and one of the most active healthcare investors in the world, having completed more than 60 healthcare acquisitions.
In addition to his responsibilities at The Riverside Company, Joseph is the President of The Healthcare Private Equity Association, (“HCPEA”). HCPEA represents one of the largest groups of privately-held healthcare businesses in the U.S. Its members’ approximately represent over $500 billion of capital under management and have 500 healthcare portfolio companies with over $200 billion of combined revenue and employ over 750,000 employees.
Prior to joining Riverside, Ibrahim was Director of Healthcare Private Equity at MBF Healthcare Partners. He also served as Vice President, GE Capital, as Vice President, Corporate Development at Cardinal Health, and as Operating Principal at Healthcare Capital Consolidated. He began his career as an Associate with Southmark Corporation. Ibrahim earned his BA from Vanderbilt University and his MBA from Wake Forest University. He resides in Atlanta.
Paul E. DiCorleto, Ph.D., is Chair of the Cleveland Clinic Lerner Research Institute (LRI) and Professor and Chair of the Department of Molecular Medicine, Case Western Reserve University School of Medicine. The LRI is home to over 175 laboratory principal investigators and ~2000 employees performing biomedical research. Dr. DiCorleto also oversees the Clinic’s Center for Clinical Research, which provides infrastructure support and oversight for all human subjects research at Cleveland Clinic. Research funding from external sources to the LRI exceeded $185 million in 2012 with over $100 million coming from the National Institutes of Health (NIH) and other Federal agencies.
Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto is a vascular cell biologist with extensive experience in the role of endothelial cell signaling pathways and gene expression in atherosclerosis and other inflammatory diseases. He has been with the Cleveland Clinic since 1982, having served previously as Chair of the Department of Cell Biology and as an Associate Chief of Staff. He is currently a member of the Clinic’s Board of Governors and Board of Trustees.
Dr. DiCorleto has published more than 125 peer-reviewed articles, invited reviews, and book chapters and has maintained continuous support from the NIH for over 30 years. Dr. DiCorleto has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has served as President of the North American Vascular Biology Organization, and is currently a member of its Scientific Advisory Board. He also serves as a member of the Association of American Medical Colleges’ Advisory Panel on Research and was elected a Fellow of the American Association for the Advancement of Science in 2007. Dr. DiCorleto has served as a consultant and Board member of multiple companies and is currently a director of Cleveland BioLabs, Inc., a publicly traded company. He has served on the Clinic’s Commercialization Council (internal focus) and Innovation Advisory Board (external focus) for many years and is on the Board of the Clinic’s Global Cardiovascular Innovation Center.
Dr. DiCorleto is a Community Board member of the Cleveland State University (CSU) Board of Trustees and a member of the Board of Directors of the CSU Research Corporation. He is also a member of the Governance Board of the Cleveland Center for Membrane and Structural Biology of Case Western Reserve University.
As a leading neurodevice entrepreneur, Geoffrey B. Thrope has achieved a successful track record of significant returns to his investors.
He founded NDI in 2002 to develop and commercialize neurodevice products, establishing three ventures and returning over 150 times the original investment back to shareholders in its first exit.
Prior to forming NDI, Mr. Thrope served as Vice President of New Business Development at NeuroControl Corporation, where he helped attract over $30 million in venture capital investment.
He is the inventor on over 60 neurostimulation patents issued and pending, and has published and presented more than 50 academic articles.
He earned a Bachelor of Science degree in Biomedical Engineering from Case Western Reserve University.
Dennis D. Stripe is President of OrthoHelix Surgical Designs, a division of Tornier,
N.V., a global medical device company.
Orthohelix was acquired by Tornier in October of 2012. Prior to the acquisition, Mr. Stripe was named
CEO of OrthoHelix in July 2008, and served on the Board of Directors. He has over 30 years of medical device
experience, with 23 years in the orthopedic sector, in various senior
management positions. Mr. Stripe has
been instrumental in building the OrthoHelix organization and growing their
business through focus on balanced team building. As an experienced executive in the orthopedic
implant market, he has knowledge of most market segments. Prior to joining OrthoHelix, Mr. Stripe held
several positions at Stryker Corp. within their spine implant division,
progressing from General Manager of the US business to Vice President of Global
Marketing. Mr. Stripe earned his BA in
Marketing from Ohio Northern University, who in 2006 awarded him an Honorary BS
Mark Brandt '86 is the director of Business Development for the audit, tax and business consulting practice in Ohio. Mark has more than 20 years of experience working with professional service, software, healthcare, investment management, private equity, manufacturing companies and start-ups. He also serves as head of the firms Private Equity practice for Ohio.
Mark founded the Maple Fund, a Venture Capital Fund focused on Software and other emerging technologies like Nanotech. He was the first investor in Nanofluidics, today called Pacific Biosciences which has since been funded by some of the best venture capital firms in the US including Kleiner Perkins. He was also a principal at a private equity fund where he was responsible for fundraising and sourcing of deals.
He started his career with Cargill Incorporated where he filled roles from commodity trader to national sales management. His clients included Gallo wines, Pfizer, Procter and Gamble, General Mills, Hoffman La Roche, Kraft, Pepsi and Coke. Mark ran a green field development of the $60,000,000 acidulates business for marketing and sales. This project had one of the quickest ROI’s in Cargill’s history.
Mark’s co-founded a venture backed software company named Notiva that brought together food retailers and their suppliers. The A/P A/R matching and reconciliation software was piloted with Procter and Gamble and Target Stores and was rolled out to SC Johnson and 14 other suppliers. The company was eventually sold to Oracle.
Mark worked at Arthur Andersen as head of business development for the Midwest consulting practice where he worked with CEO, CFO, and CIO’s VP’s for many of the most successful companies in the region.
Professional Affiliations and Credentials
ACG Member of Cleveland Chapter
Graduate of Cornell University, Business Management and Marketing, Bachelor of Science degree